Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI

NCT00751231 is registered in ClinicalTrials.gov with Portola Pharmaceuticals as lead sponsor.

NCT NCT00751231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00751231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI
Lead sponsor
Portola Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
April 30, 2010
Enrollment
652 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

percutaneous coronary intervention